Tasosartan
From Wikipedia, the free encyclopedia
|
Tasosartan
|
|
| Systematic (IUPAC) name | |
| 2,4-dimethyl-8-[ [4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one | |
| Identifiers | |
| CAS number | ? |
| ATC code | C09 |
| PubChem | |
| Chemical data | |
| Formula | C23H21N7O |
| Mol. mass | 411.459 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tasosartan is an angiotensin II receptor antagonist.
|
|||||||||||

